Pipeline
Novartis-Partnered Product Candidates
We also have two products partnered with Novartis in our pipeline: HCD122, a monoclonal antibody to CD40 currently in Phase 1/2 clinical trials for the treatment of lymphoma, and LFA102, a monoclonal antibody to the prolactin receptor in development for the treatment of certain breast or prostate cancers.
 |
| Image courtesy Novartis Oncology |
